68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

被引:106
作者
Brom, Maarten [1 ]
Oyen, Wim J. G. [1 ]
Joosten, Lieke [1 ]
Gotthardt, Martin [1 ]
Boerman, Otto C. [1 ]
机构
[1] Radboud Univ Nijmegen Med Ctr, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词
Insulinoma; GLP-1; receptor; Imaging; SPECT; PET; Exendin; GLP-1; BINDING-SITES; NEUROENDOCRINE TUMORS; RECEPTOR SCINTIGRAPHY; PEPTIDE-1; LOCALIZATION; LIGAND;
D O I
10.1007/s00259-009-1363-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Insulinomas are neuroendocrine tumours derived from pancreatic beta-cells. The glucagon-like peptide 1 receptor (GLP-1R) is expressed with a high incidence (> 90%) and high density in insulinomas. Glucagon-like peptide 1 (GLP-1), the natural ligand of GLP-1R, is rapidly degraded in vivo. A more stable agonist of GLP-1R is exendin-3. We investigated imaging of insulinomas with DOTA-conjugated exendin-3 labelled with Ga-68. Targeting of insulinomas with [Lys(40)(DOTA)]exendin-3 labelled with either In-111 or Ga-68 was investigated in vitro using insulinoma tumour cells (INS-1). [Lys(40)(In-111-DTPA)]Exendin-3 was used as a reference in this study. In vivo targeting was investigated in BALB/c nude mice with subcutaneous INS-1 tumours. PET imaging was performed using a preclinical PET/CT scanner. In vitro exendin-3 specifically bound and was internalized by GLP-1R-positive cells. In BALB/c nude mice with subcutaneous INS-1 tumours a high uptake of [Lys(40)(In-111-DTPA)]exendin-3 in the tumour was observed (33.5 +/- 11.6%ID/g at 4 h after injection). Uptake was specific, as determined by coinjection of an excess of unlabelled [Lys(40)]exendin-3 (1.8 +/- 0.1%ID/g). The pancreas also exhibited high and specific uptake (11.3 +/- 1.0%ID/g). High uptake was also found in the kidneys (144 +/- 24%ID/g) and this uptake was not receptor-mediated. In this murine tumour model optimal targeting of the GLP-1R expressing tumour was obtained at exendin doses a parts per thousand currency sign0.1 A mu g. Remarkably, tumour uptake of Ga-68-labelled [Lys(40)(DOTA)]exendin-3 was lower (8.9 A +/- 3.1%ID/g) than tumour uptake of In-111-labelled [Lys(40)(DTPA)]exendin-3 (25.4 A +/- 7.2%ID/g). The subcutaneous tumours were clearly visualized by small-animal PET imaging after injection of 3 MBq of [Lys(40)(Ga-68-DOTA)]exendin-3. [Lys(40)(Ga-68-DOTA)]Exendin-3 specifically accumulates in insulinomas, although the uptake is lower than that of [Lys(40)(In-111-DTPA)]exendin-3. Therefore, [Lys(40)(Ga-68-DOTA)]exendin-3 is a promising tracer to visualize insulinomas with PET.
引用
收藏
页码:1345 / 1355
页数:11
相关论文
共 25 条
[1]   Occult sporadic insulinoma: Localization and surgical strategy [J].
Abboud, Bassam ;
Boujaoude, Joe .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (05) :657-665
[2]   Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? [J].
Antunes, P. ;
Ginj, M. ;
Zhang, H. ;
Waser, B. ;
Baum, R. P. ;
Reubi, J. C. ;
Maecke, H. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (07) :982-993
[3]   ESTABLISHMENT OF 2-MERCAPTOETHANOL-DEPENDENT DIFFERENTIATED INSULIN-SECRETING CELL-LINES [J].
ASFARI, M ;
JANJIC, D ;
MEDA, P ;
LI, GD ;
HALBAN, PA ;
WOLLHEIM, CB .
ENDOCRINOLOGY, 1992, 130 (01) :167-178
[4]   Radiolabelling DOTA-peptides with 68Ga [J].
Breeman, WAP ;
de Jong, M ;
de Blois, E ;
Bernard, BF ;
Konijnenberg, M ;
Krenning, EP .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (04) :478-485
[5]  
Brom M, 2009, J NUCL MED, V50
[6]   Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours [J].
Buchmann, I. ;
Henze, M. ;
Engelbrecht, S. ;
Eisenhut, M. ;
Runz, A. ;
Schaefer, M. ;
Schilling, T. ;
Haufe, S. ;
Herrmann, T. ;
Haberkorn, U. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (10) :1617-1626
[7]   DISTRIBUTION OF GLP-1 BINDING-SITES IN THE RAT-BRAIN - EVIDENCE THAT EXENDIN-4 IS A LIGAND OF BRAIN GLP-1 BINDING-SITES [J].
GOKE, R ;
LARSEN, PJ ;
MIKKELSEN, JD ;
SHEIKH, SP .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1995, 7 (11) :2294-2300
[8]   Development and clinical application of peptide-based radiopharmaceuticals [J].
Gotthardt, M ;
Boermann, OC ;
Behr, TM ;
Béhé, MP ;
Oyen, WJG .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (24) :2951-2963
[9]   Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas:: initial experimental results [J].
Gotthardt, M ;
Fischer, M ;
Naeher, I ;
Holz, JB ;
Jungclas, H ;
Fritsch, HW ;
Béhé, M ;
Göke, B ;
Joseph, K ;
Behr, TM .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (05) :597-606
[10]   A new technique for in vivo imaging of specific GLP-1 binding sites:: First results in small rodents [J].
Gotthardt, Martin ;
Lalyko, Georg ;
van Eerd-Vismale, Julliette ;
Keil, Boris ;
Schurrat, Tino ;
Hower, Michael ;
Laverman, Peter ;
Behr, Thomas M. ;
Boerman, Otto C. ;
Goeke, Burkhard ;
Behe, Martin .
REGULATORY PEPTIDES, 2006, 137 (03) :162-167